{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T11:01:04Z","timestamp":1788346864885,"version":"build-2803163510"},"publisher-location":"Dordrecht","reference-count":69,"publisher":"Springer Netherlands","isbn-type":[{"value":"9789400765511","type":"print"},{"value":"9789400765528","type":"electronic"}],"license":[{"start":{"date-parts":[[2013,1,1]],"date-time":"2013-01-01T00:00:00Z","timestamp":1356998400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2013,1,1]],"date-time":"2013-01-01T00:00:00Z","timestamp":1356998400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013]]},"DOI":"10.1007\/978-94-007-6552-8_20","type":"book-chapter","created":{"date-parts":[[2013,6,4]],"date-time":"2013-06-04T11:14:35Z","timestamp":1370344475000},"page":"599-630","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Antiviral Agents: Structural Basis of Action and Rational Design"],"prefix":"10.1007","author":[{"given":"Luis","family":"Men\u00e9ndez-Arias","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Gago","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,4,19]]},"reference":[{"key":"20_CR00201","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1038\/nrmicro975","volume":"2","author":"E De Clercq","year":"2004","unstructured":"De Clercq E (2004) Antivirals and antiviral strategies. Nat Rev Microbiol 2:704\u2013720","journal-title":"Nat Rev Microbiol"},{"key":"20_CR00202","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.ijantimicag.2008.10.010","volume":"33","author":"E De Clercq","year":"2009","unstructured":"De Clercq E (2009) Anti-HIV drugs: 25 compounds approved within 25 years after the discovery of HIV. Int J Antimicrob Agents 33:307\u2013320","journal-title":"Int J Antimicrob Agents"},{"key":"20_CR00203","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.antiviral.2009.07.006","volume":"85","author":"L Men\u00e9ndez-Arias","year":"2010","unstructured":"Men\u00e9ndez-Arias L (2010) Molecular basis of human immunodeficiency virus drug resistance: an update. Antiviral Res 85:210\u2013213","journal-title":"Antiviral Res"},{"key":"20_CR00204","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.3390\/v1031137","volume":"1","author":"L Men\u00e9ndez-Arias","year":"2009","unstructured":"Men\u00e9ndez-Arias L (2009) Mutation rates and intrinsic fidelity of retroviral reverse transcriptases. Viruses 1:1137\u20131165","journal-title":"Viruses"},{"key":"20_CR00205","doi-asserted-by":"crossref","first-page":"305","DOI":"10.4049\/jimmunol.67.4.305","volume":"67","author":"D Hamre","year":"1951","unstructured":"Hamre D, Brownlee KA, Donovick R (1951) Studies on the chemotherapy of vaccinia virus. II The activity of some thiosemicarbazones. J Immunol 67:305\u2013312","journal-title":"J Immunol"},{"key":"20_CR00206","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1016\/S0140-6736(63)90230-7","volume":"2","author":"DJ Bauer","year":"1963","unstructured":"Bauer DJ, St. Vincent L, Kempe CH, Downie AW (1963) Prophylactic treatment of smallpox contacts with N-methylisatin \u03b2-thiosemicarbazone (compound 33T57, Marboran). Lancet 2:494\u2013496","journal-title":"Lancet"},{"key":"20_CR00207","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/0006-3002(59)90597-9","volume":"32","author":"WH Prusoff","year":"1959","unstructured":"Prusoff WH (1959) Synthesis and biological activities of iododeoxyuridine, an analog of thymidine. Biochim Biophys Acta 32:295\u2013296","journal-title":"Biochim Biophys Acta"},{"key":"20_CR00208","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1016\/j.drudis.2009.04.005","volume":"14","author":"AM Jordan","year":"2009","unstructured":"Jordan AM, Roughley SD (2009) Drug discovery chemistry: a primer for the non-specialist. Drug Discov Today 14:731\u2013744","journal-title":"Drug Discov Today"},{"key":"20_CR00209","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1038\/nrd1877","volume":"4","author":"E De Clercq","year":"2005","unstructured":"De Clercq E, Hol\u00fd A (2005) Acyclic nucleoside phosphonates: a key class of antiviral drugs. Nat Rev Drug Discov 4:928\u2013940","journal-title":"Nat Rev Drug Discov"},{"key":"20_CR002010","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.virusres.2007.12.015","volume":"134","author":"L Men\u00e9ndez-Arias","year":"2008","unstructured":"Men\u00e9ndez-Arias L (2008) Mechanisms of resistance to nucleoside analogue inhibitors of HIV-1 reverse transcriptase. Virus Res 134:124\u2013146","journal-title":"Virus Res"},{"key":"20_CR002011","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.antiviral.2011.08.020","volume":"92","author":"L Men\u00e9ndez-Arias","year":"2011","unstructured":"Men\u00e9ndez-Arias L, Betancor G, Matamoros T (2011) HIV-1 reverse transcriptase connection subdomain mutations involved in resistance to approved non-nucleoside inhibitors. Antiviral Res 92:139\u2013149","journal-title":"Antiviral Res"},{"key":"20_CR002012","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1021\/jm040127p","volume":"48","author":"BL De Corte","year":"2005","unstructured":"De Corte BL (2005) From 4,5,6,7-tetrahydro-5-methylimidazo[4,5,1-jk](1,4)benzodiazepin-2(1H)-one (TIBO) to etravirine (TMC125): Fifteen years of research on non-nucleoside inhibitors of HIV-1 reverse transcriptase. J Med Chem 48:1689\u20131696","journal-title":"J Med Chem"},{"key":"20_CR002013","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1021\/jm040840e","volume":"48","author":"PAJ Janssen","year":"2005","unstructured":"Janssen PAJ, Lewi PJ, Arnold E et al (2005) In search of a novel anti-HIV drug: multidisciplinary coordination in the discovery of 4-[[4-[[-[(1E)-2-cyanoethenyl]-2, 6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile (R278474, rilpivirine). J Med Chem 48:1901\u20131909","journal-title":"J Med Chem"},{"key":"20_CR002014","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.virusres.2007.12.024","volume":"134","author":"M Nassal","year":"2008","unstructured":"Nassal M (2008) Hepatitis B viruses: reverse transcription a different way. Virus Res 134:235\u2013249","journal-title":"Virus Res"},{"key":"20_CR002015","first-page":"441","volume":"13","author":"WJ Watkins","year":"2010","unstructured":"Watkins WJ, Ray AS, Chong LS (2010) HCV NS5B polymerase inhibitors. Curr Opin Drug Discov Devel 13:441\u2013465","journal-title":"Curr Opin Drug Discov Devel"},{"key":"20_CR002016","doi-asserted-by":"publisher","first-page":"3150","DOI":"10.1016\/j.bmc.2012.03.049","volume":"20","author":"AS Mayhoub","year":"2012","unstructured":"Mayhoub AS (2012) Hepatitis C RNA-dependent RNA polymerase inhibitors: a review of structure-activity and resistance relationships; different scaffolds and mutations. Bioorg Med Chem 20:3150\u20133161","journal-title":"Bioorg Med Chem"},{"key":"20_CR002017","doi-asserted-by":"publisher","first-page":"7202","DOI":"10.1021\/jm100863x","volume":"53","author":"MJ Sofia","year":"2010","unstructured":"Sofia MJ, Bao D, Chang W et al (2010) Discovery of a \u03b2-D-2\u2032-deoxy-2\u2032-\u03b1-fluoro-2\u2032-\u03b2-C-methyluridine nucleotide prodrug (PSI-7977) for the treatment of hepatitis C virus. J Med Chem 53:7202\u20137218","journal-title":"J Med Chem"},{"key":"20_CR002018","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1038\/nrd2424","volume":"6","author":"E De Clercq","year":"2007","unstructured":"De Clercq E (2007) The design of drugs for HIV and HCV. Nat Rev Drug Discov 6:1001\u20131018","journal-title":"Nat Rev Drug Discov"},{"key":"20_CR002019","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1038\/nature08960","volume":"465","author":"M Gao","year":"2010","unstructured":"Gao M, Nettles RE, Belema M et al (2010) Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect. Nature 465:96\u2013100","journal-title":"Nature"},{"key":"20_CR002020","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1128\/JVI.01360-09","volume":"84","author":"JA Lemm","year":"2010","unstructured":"Lemm JA, O\u2019Boyle D 2nd, Liu M et al (2010) Identification of hepatitis C virus NS5A inhibitors. J Virol 84:482\u2013491","journal-title":"J Virol"},{"key":"20_CR002021","doi-asserted-by":"publisher","first-page":"e13687","DOI":"10.1371\/journal.pone.0013687","volume":"5","author":"L Coelmont","year":"2010","unstructured":"Coelmont L, Hanoulle X, Chatterji U et al (2010) DEB025 (Alisporivir) inhibits hepatitis C virus replication by preventing a cyclophilin A induced cis-trans isomerisation in domain II of NS5A. PLoS One 5:e13687","journal-title":"PLoS One"},{"key":"20_CR002022","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1146\/annurev.pharmtox.011008.145553","volume":"49","author":"D Hazuda","year":"2008","unstructured":"Hazuda D, Iwamoto M, Wenning L (2008) Emerging pharmacology: inhibitors of human immunodeficiency virus integration. Annu Rev Pharmacol Toxicol 49:377\u2013394","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"20_CR002023","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/1742-4690-6-25","volume":"6","author":"E Serrao","year":"2009","unstructured":"Serrao E, Odde S, Ramkumar K, Neamati N (2009) Raltegravir, elvitegravir, and metoogravir: the birth of \u201cme-too\u201d HIV-1 integrase inhibitors. Retrovirology 6:25","journal-title":"Retrovirology"},{"key":"20_CR002024","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.sbi.2010.12.005","volume":"21","author":"P Cherepanov","year":"2011","unstructured":"Cherepanov P, Maertens GN, Hare S (2011) Structural insights into the retroviral DNA integration apparatus. Curr Opin Struct Biol 21:249\u2013256","journal-title":"Curr Opin Struct Biol"},{"key":"20_CR002025","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1021\/ar700109k","volume":"41","author":"FG Njoroge","year":"2008","unstructured":"Njoroge FG, Chen KX, Shih NY, Piwinski JJ (2008) Challenges in modern drug discovery: a case study of boceprevir, an HCV protease inhibitor for the treatment of hepatitis C virus infection. Acc Chem Res 41:50\u201359","journal-title":"Acc Chem Res"},{"key":"20_CR002026","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1038\/nbt.2020","volume":"29","author":"AD Kwong","year":"2011","unstructured":"Kwong AD, Kauffman RS, Hurter P, Mueller P (2011) Discovery and development of telaprevir: an NS3-4A protease inhibitor for treating genotype 1 chronic hepatitis C virus. Nat Biotechnol 29:993\u20131003","journal-title":"Nat Biotechnol"},{"key":"20_CR002027","doi-asserted-by":"publisher","first-page":"2273","DOI":"10.1016\/j.bcp.2003.08.001","volume":"66","author":"HJ Hacker","year":"2003","unstructured":"Hacker HJ, Deres K, Mildenberger M, Schr\u00f6der CH (2003) Antivirals interacting with hepatitis B virus core protein and core mutations may misdirect capsid assembly in a similar fashion. Biochem Pharmacol 66:2273\u20132279","journal-title":"Biochem Pharmacol"},{"key":"20_CR002028","doi-asserted-by":"publisher","first-page":"8138","DOI":"10.1073\/pnas.0409732102","volume":"102","author":"SJ Stray","year":"2005","unstructured":"Stray SJ, Bourne CR, Punna S et al (2005) A heteroaryldihydropyrimidine activates and can misdirect hepatitis B virus capsid assembly. Proc Natl Acad Sci USA 102:8138\u20138143","journal-title":"Proc Natl Acad Sci USA"},{"key":"20_CR002029","doi-asserted-by":"publisher","first-page":"6110","DOI":"10.1111\/j.1742-4658.2009.07314.x","volume":"276","author":"JL Neira","year":"2009","unstructured":"Neira JL (2009) The capsid protein of human immunodeficiency virus: designing inhibitors of capsid assembly. FEBS J 276:6110\u20136117","journal-title":"FEBS J"},{"key":"20_CR002030","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1016\/j.jmb.2011.03.074","volume":"410","author":"PE Prevelige Jr","year":"2011","unstructured":"Prevelige PE Jr (2011) New approaches for antiviral targeting of HIV assembly. J Mol Biol 410:634\u2013640","journal-title":"J Mol Biol"},{"key":"20_CR002031","doi-asserted-by":"publisher","first-page":"28403","DOI":"10.1074\/jbc.R110.129809","volume":"285","author":"SJ Gamblin","year":"2010","unstructured":"Gamblin SJ, Skehel JJ (2010) Influenza hemagglutinin and neuraminidase membrane glycoproteins. J Biol Chem 285:28403\u201328409","journal-title":"J Biol Chem"},{"key":"20_CR002032","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.2174\/1381612043384574","volume":"10","author":"L Men\u00e9ndez-Arias","year":"2004","unstructured":"Men\u00e9ndez-Arias L, Est\u00e9 JA (2004) HIV-resistance to viral entry inhibitors. Curr Pharm Des 10:1845\u20131860","journal-title":"Curr Pharm Des"},{"key":"20_CR002033","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1016\/j.str.2008.09.005","volume":"16","author":"N Madani","year":"2008","unstructured":"Madani N, Sch\u00f6n A, Princiotto AM et al (2008) Small-molecule CD4 mimics interact with a highly conserved pocket on HIV-1 gp120. Structure 16:1689\u20131701","journal-title":"Structure"},{"key":"20_CR002034","doi-asserted-by":"publisher","first-page":"4764","DOI":"10.1021\/jm3002247","volume":"55","author":"F Curreli","year":"2012","unstructured":"Curreli F, Choudhury S, Pyatkin I et al (2012) Design, synthesis, and antiviral activity of entry inhibitors that target the CD4-binding site of HIV-1. J Med Chem 55:4764\u20134775","journal-title":"J Med Chem"},{"key":"20_CR002035","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1146\/annurev.biochem.78.082207.084029","volume":"78","author":"PM Colman","year":"2009","unstructured":"Colman PM (2009) New antivirals and drug resistance. Annu Rev Biochem 78:95\u2013118","journal-title":"Annu Rev Biochem"},{"key":"20_CR002036","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1073\/pnas.0910108106","volume":"107","author":"D Roymans","year":"2010","unstructured":"Roymans D, De Bondt HL, Arnoult E et al (2010) Binding of a potent small-molecule inhibitor of six-helix bundle formation requires interactions with both heptad-repeats of the RSV fusion protein. Proc Natl Acad Sci USA 107:308\u2013313","journal-title":"Proc Natl Acad Sci USA"},{"key":"20_CR002037","doi-asserted-by":"crossref","unstructured":"Chen GS, Chern J-W (2007) Computer-aided drug design. In: Hwang Z (ed) Drug discovery research: new frontiers in the post-genomic era. Wiley, Hoboken, pp 89\u2013107","DOI":"10.1002\/9780470131862.ch4"},{"key":"20_CR002038","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1016\/j.cbpa.2007.08.033","volume":"11","author":"C McInnes","year":"2007","unstructured":"McInnes C (2007) Virtual screening strategies in drug discovery. Curr Opin Chem Biol 11:494\u2013502","journal-title":"Curr Opin Chem Biol"},{"key":"20_CR002039","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1021\/ci049714+","volume":"45","author":"JJ Irwin","year":"2005","unstructured":"Irwin JJ, Shoichet BK (2005) ZINC\u2013a free database of commercially available compounds for virtual screening. J Chem Inf Model 45:177\u2013182","journal-title":"J Chem Inf Model"},{"key":"20_CR002040","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/S0169-409X(00)00129-0","volume":"46","author":"CA Lipinski","year":"2001","unstructured":"Lipinski CA, Lombardo F, Dominy BW, Feeney PJ (2001) Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 46:3\u201326","journal-title":"Adv Drug Deliv Rev"},{"key":"20_CR002041","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1007\/978-1-60761-839-3_11","volume":"672","author":"D Horvath","year":"2011","unstructured":"Horvath D (2011) Pharmacophore-based virtual screening. Methods Mol Biol 672:261\u2013298","journal-title":"Methods Mol Biol"},{"key":"20_CR002042","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1038\/nrd1549","volume":"3","author":"DB Kitchen","year":"2004","unstructured":"Kitchen DB, Decornez H, Furr JR, Bajorath J (2004) Docking and scoring in virtual screening for drug discovery: methods and applications. Nat Rev Drug Discov 3:935\u2013949","journal-title":"Nat Rev Drug Discov"},{"key":"20_CR002043","doi-asserted-by":"publisher","first-page":"37","DOI":"10.2174\/092986708783330683","volume":"15","author":"RV Guido","year":"2008","unstructured":"Guido RV, Oliva G, Andricopulo AD (2008) Virtual screening and its integration with modern drug design technologies. Curr Med Chem 15:37\u201346","journal-title":"Curr Med Chem"},{"key":"20_CR002044","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1007\/s10822-011-9451-z","volume":"25","author":"C Sun","year":"2011","unstructured":"Sun C, Petros AM, Hajduk PJ (2011) Fragment-based lead discovery: challenges and opportunities. J Comput Aided Mol Des 25:607\u2013610","journal-title":"J Comput Aided Mol Des"},{"key":"20_CR002045","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1016\/j.drudis.2010.08.004","volume":"15","author":"C Abad-Zapatero","year":"2010","unstructured":"Abad-Zapatero C, Peri\u0161i\u0107 O, Wass J et al (2010) Ligand efficiency indices for an effective mapping of chemico-biological space: the concept of an atlas-like representation. Drug Discov Today 15:804\u2013811","journal-title":"Drug Discov Today"},{"key":"20_CR002046","doi-asserted-by":"publisher","first-page":"W387","DOI":"10.1093\/nar\/gks336","volume":"40","author":"DR Koes","year":"2012","unstructured":"Koes DR, Camacho CJ (2012) PocketQuery: protein-protein interaction inhibitor starting points from protein-protein interaction structure. Nucleic Acids Res 40:W387\u2013W392","journal-title":"Nucleic Acids Res"},{"key":"20_CR002047","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1021\/ci200468p","volume":"52","author":"DR Hall","year":"2012","unstructured":"Hall DR, Ngan CH, Zerbe BS, Kozakov D, Vajda S (2012) Hot spot analysis for driving the development of hits into leads in fragment-based drug discovery. J Chem Inf Model 52:199\u2013209","journal-title":"J Chem Inf Model"},{"key":"20_CR002048","doi-asserted-by":"publisher","first-page":"2718","DOI":"10.1021\/ja038893t","volume":"126","author":"F Rodr\u00edguez-Barrios","year":"2004","unstructured":"Rodr\u00edguez-Barrios F, Gago F (2004) Chemometrical identification of mutations in HIV-1 reverse transcriptase conferring resistance or enhanced sensitivity to arylsulfonylbenzonitriles. J Am Chem Soc 126:2718\u20132719","journal-title":"J Am Chem Soc"},{"key":"20_CR002049","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/303035a0","volume":"303","author":"JN Varghese","year":"1983","unstructured":"Varghese JN, Laver WG, Colman PM (1983) Structure of the influenza virus glycoprotein antigen neuraminidase at 2.9 \u00c5 resolution. Nature 303:35\u201340","journal-title":"Nature"},{"key":"20_CR002050","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1038\/nrd2400","volume":"6","author":"M Von Itzstein","year":"2007","unstructured":"Von Itzstein M (2007) The war against influenza: discovery and development of sialidase inhibitors. Nat Rev Drug Discov 6:967\u2013974","journal-title":"Nat Rev Drug Discov"},{"key":"20_CR002051","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1038\/nature06956","volume":"453","author":"PJ Collins","year":"2008","unstructured":"Collins PJ, Haire LF, Lin YP et al (2008) Crystal structures of oseltamivir-resistant influenza virus neuraminidase mutants. Nature 453:1258\u20131261","journal-title":"Nature"},{"key":"20_CR002052","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1126\/science.2183354","volume":"248","author":"NA Roberts","year":"1990","unstructured":"Roberts NA, Martin JA, Kinchington D et al (1990) Rational design of peptide-based HIV proteinase inhibitors. Science 248:358\u2013361","journal-title":"Science"},{"key":"20_CR002053","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1002\/anie.201102762","volume":"51","author":"AK Ghosh","year":"2012","unstructured":"Ghosh AK, Anderson DD, Weber IT, Mitsuya H (2012) Enhancing protein backbone binding \u2013 a fruitful concept for combating drug-resistant HIV. Angew Chem Int Ed Engl 51:1778\u20131802","journal-title":"Angew Chem Int Ed Engl"},{"key":"20_CR002054","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.antiviral.2006.03.011","volume":"71","author":"AK Patick","year":"2006","unstructured":"Patick AK (2006) Rhinovirus chemotherapy. Antiviral Res 71:391\u2013396","journal-title":"Antiviral Res"},{"key":"20_CR002055","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.antiviral.2005.08.003","volume":"68","author":"RM Ledford","year":"2005","unstructured":"Ledford RM, Collett MS, Pevear DC (2005) Insights into the genetic basis for natural phenotypic resistance of human rhinoviruses to pleconaril. Antiviral Res 68:135\u2013138","journal-title":"Antiviral Res"},{"key":"20_CR002056","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.bcp.2011.08.016","volume":"83","author":"HJ Thibaut","year":"2012","unstructured":"Thibaut HJ, De Palma AM, Neyts J (2012) Combating enterovirus replication: state-of-the-art on antiviral research. Biochem Pharmacol 83:185\u2013192","journal-title":"Biochem Pharmacol"},{"key":"20_CR002057","doi-asserted-by":"publisher","first-page":"4501","DOI":"10.1128\/AAC.00671-09","volume":"53","author":"MS Oberste","year":"2009","unstructured":"Oberste MS, Moore D, Anderson B et al (2009) In vitro antiviral activity of V-073 against polioviruses. Antimicrob Agents Chemother 53:4501\u20134503","journal-title":"Antimicrob Agents Chemother"},{"key":"20_CR002058","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/1743-422X-4-40","volume":"4","author":"AL Kistler","year":"2007","unstructured":"Kistler AL, Webster DR, Rouskin S et al (2007) Genome-wide diversity and selective pressure in the human rhinovirus. Virol J 4:40","journal-title":"Virol J"},{"key":"20_CR002059","doi-asserted-by":"publisher","first-page":"4848","DOI":"10.1128\/JVI.76.10.4848-4854.2002","volume":"76","author":"A Zlotnick","year":"2002","unstructured":"Zlotnick A, Ceres P, Singh S, Johnson JM (2002) A small molecule inhibits and misdirects assembly of hepatitis B virus capsids. J Virol 76:4848\u20134854","journal-title":"J Virol"},{"key":"20_CR002060","doi-asserted-by":"publisher","first-page":"11055","DOI":"10.1128\/JVI.00933-06","volume":"80","author":"CR Bourne","year":"2006","unstructured":"Bourne CR, Finn MG, Zlotnick A (2006) Global structural changes in hepatitis B virus capsids induced by the assembly effector HAP1. J Virol 80:11055\u201311061","journal-title":"J Virol"},{"key":"20_CR002061","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1002\/jmr.801","volume":"19","author":"SJ Stray","year":"2006","unstructured":"Stray SJ, Zlotnick A (2006) BAY 41\u20134109 has multiple effects on hepatitis B virus capsid assembly. J Mol Recognit 19:542\u2013548","journal-title":"J Mol Recognit"},{"key":"20_CR002062","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1016\/j.drudis.2008.02.003","volume":"13","author":"CS Adamson","year":"2008","unstructured":"Adamson CS, Freed EO (2008) Recent progress in antiretrovirals \u2013 lessons from resistance. Drug Discov Today 13:424\u2013432","journal-title":"Drug Discov Today"},{"key":"20_CR002063","doi-asserted-by":"publisher","first-page":"5080","DOI":"10.1128\/AAC.00759-09","volume":"53","author":"WS Blair","year":"2009","unstructured":"Blair WS, Cao J, Fok-Seang J et al (2009) New small-molecule inhibitor class targeting human immunodeficiency virus type 1 virion maturation. Antimicrob Agents Chemother 53:5080\u20135087","journal-title":"Antimicrob Agents Chemother"},{"key":"20_CR002064","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1016\/j.cell.2009.04.063","volume":"137","author":"O Pornillos","year":"2009","unstructured":"Pornillos O, Ganser-Pornillos BK, Kelly BN et al (2009) X-ray structures of the hexameric building block of the HIV capsid. Cell 137:1282\u20131292","journal-title":"Cell"},{"key":"20_CR002065","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/j.virusres.2012.06.016","volume":"169","author":"R Bocanegra","year":"2012","unstructured":"Bocanegra R, Rodr\u00edguez-Huete A, Fuertes MA et al (2012) Molecular recognition in the human immunodeficiency virus capsid and antiviral design. Virus Res 169:388\u2013410","journal-title":"Virus Res"},{"key":"20_CR002066","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/1742-4690-8-28","volume":"8","author":"H Zhang","year":"2011","unstructured":"Zhang H, Curreli F, Zhang X et al (2011) Antiviral activity of \u03b1-helical stapled peptides designed from the HIV-1 capsid dimerization domain. Retrovirology 8:28","journal-title":"Retrovirology"},{"key":"20_CR002067","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1128\/JVI.01406-10","volume":"85","author":"J Shi","year":"2011","unstructured":"Shi J, Zhou J, Shah VB et al (2011) Small-molecule inhibition of human immunodeficiency virus type 1 infection by virus capsid destabilization. J Virol 85:542\u2013549","journal-title":"J Virol"},{"key":"20_CR002068","doi-asserted-by":"publisher","first-page":"e1001220","DOI":"10.1371\/journal.ppat.1001220","volume":"6","author":"WS Blair","year":"2010","unstructured":"Blair WS, Pickford C, Irving SL et al (2010) HIV capsid is a tractable target for small molecule therapeutic intervention. PLoS Pathog 6:e1001220","journal-title":"PLoS Pathog"},{"key":"20_CR002069","doi-asserted-by":"publisher","first-page":"6643","DOI":"10.1128\/JVI.00493-12","volume":"86","author":"CT Lemke","year":"2012","unstructured":"Lemke CT, Titolo S, von Schwedler U et al (2012) Distinct effects of two HIV-1 capsid assembly inhibitor families that bind the same site within the N-terminal domain of the viral CA protein. J Virol 86:6643\u20136655","journal-title":"J Virol"}],"container-title":["Subcellular Biochemistry","Structure and Physics of Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-94-007-6552-8_20","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,9]],"date-time":"2023-02-09T16:07:07Z","timestamp":1675958827000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-94-007-6552-8_20"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013]]},"ISBN":["9789400765511","9789400765528"],"references-count":69,"URL":"https:\/\/doi.org\/10.1007\/978-94-007-6552-8_20","relation":{},"ISSN":["0306-0225"],"issn-type":[{"value":"0306-0225","type":"print"}],"subject":[],"published":{"date-parts":[[2013]]},"assertion":[{"value":"19 April 2013","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}